Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 29;10(8):1217.
doi: 10.3390/vaccines10081217.

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination

Oleguer Parés-Badell  1   2 , Ricardo Zules-Oña  1   2 , Lluís Armadans  1   2   3 , Laia Pinós  1   2 , Blanca Borrás-Bermejo  1   2   3 , Susana Otero  1   2   3 , José Ángel Rodrigo-Pendás  1   2   3 , Martí Vivet-Escalé  1   2 , Yolima Cossio-Gil  4   5 , Antònia Agustí  6   7 , Cristina Aguilera  6 , Magda Campins  2 , Xavier Martínez-Gómez  1   2   3
Affiliations

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination

Oleguer Parés-Badell et al. Vaccines (Basel). .

Abstract

The objective of this study was to assess the local and systemic adverse reactions after the administration of a COVID-19 mRNA-1273 booster between December 2021 and February 2022 by comparing the type of mRNA vaccine used as primary series (mRNA-1273 or BNT162b2) and homologous versus heterologous booster in health care workers (HCW). A cross-sectional study was performed in HCW at a tertiary hospital in Barcelona, Spain. A total of 17% of booster recipients responded to the questionnaire. The frequency of reactogenicity after the mRNA-1273 booster (88.5%) was similar to the mRNA-1273 primary doses (85.8%), and higher than the BNT162b2 primary doses (71.1%). The reactogenicity was similar after receiving a heterologous booster compared to a homologous booster (88.0% vs. 90.2%, p = 0.3), and no statistically significant differences were identified in any local or systemic reactions. A higher frequency of medical leave was identified in the homologous booster dose group vs. the heterologous booster dose group (AOR 1.45; 95% CI: 1.00-2.07; p = 0.045). Our findings could be helpful in improving vaccine confidence toward heterologous combinations in the general population and in health care workers.

Keywords: COVID-19-vaccination; SARS-CoV-2; adverse reactions; booster dose; health care workers; mRNA vaccines.

PubMed Disclaimer

Conflict of interest statement

M.C. has received compensation for consulting services and speaking contracts from G.S.K., Novartis, Sanofi Pasteur, M.S.D., Pfizer, and Sequirus. X.M.G., B.B.B., S.O.R., J.Á.R.P., and M.C. have participated in COVID-19 vaccine research sponsored by Janssen, Pfizer, and HIPRA. M.V.E has participated in COVID-19 vaccine research sponsored by Janssen and HIPRA. R.Z.O has participated in COVID-19 vaccine research sponsored by Janssen. O.P.B. has participated in COVID-19 vaccine research sponsored by HIPRA.

Figures

Figure 1
Figure 1
The self-reported adverse reactions to the COVID-19 vaccination when comparing the primary doses versus the booster.
See this image and copyright information in PMC

References

    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed
    1. Rotshild V., Hirsh-Raccah B., Miskin I., Muszkat M., Matok I. Comparing the clinical efficacy of COVID-19 vaccines: A systematic review and network meta-analysis. Sci. Rep. 2021;11:22777. doi: 10.1038/s41598-021-02321-z. - DOI - PMC - PubMed
    1. Pegu A., O’Connell S.E., Schmidt S.D., O’Dell S., Talana C.A., Lai L., Albert J., Anderson E., Bennett H., Corbett K.S., et al. Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants. Science. 2021;373:1372–1377. doi: 10.1126/science.abj4176. - DOI - PMC - PubMed
    1. Grupo de Trabajo de Efectividad de Vacunación COVID-19 . Análisis de la Efectividad de la Vacuna Frente a COVID-19 en España. Gobierno de España, Ministerio de Sanidad; Madrid, Spain: 2021. [(accessed on 27 July 2022)]. pp. 1–30. Available online: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacu....

LinkOut - more resources